Cargando…

Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer

The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of non-small cell lung cancer (NSCLC), with these drugs now being evaluated at every stage of the disease. In contrast to these advances, little progress has been made with respect to reliable predictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcos Rubio, Alvaro, Everaert, Celine, Van Damme, Eufra, De Preter, Katleen, Vermaelen, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401220/
https://www.ncbi.nlm.nih.gov/pubmed/37536935
http://dx.doi.org/10.1136/jitc-2023-007023
_version_ 1785084609982103552
author Marcos Rubio, Alvaro
Everaert, Celine
Van Damme, Eufra
De Preter, Katleen
Vermaelen, Karim
author_facet Marcos Rubio, Alvaro
Everaert, Celine
Van Damme, Eufra
De Preter, Katleen
Vermaelen, Karim
author_sort Marcos Rubio, Alvaro
collection PubMed
description The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of non-small cell lung cancer (NSCLC), with these drugs now being evaluated at every stage of the disease. In contrast to these advances, little progress has been made with respect to reliable predictive biomarkers that can inform clinicians on therapeutic efficacy. All current biomarkers for outcome prediction, including PD-L1, tumor mutational burden or complex immune gene expression signatures, require access to tumor tissue. Besides the invasive nature of the sampling procedure, other disadvantages of tumor tissue biopsies are the inability to capture the complete spatial heterogeneity of the tumor and the difficulty to perform longitudinal follow-up on treatment. A concept emerges in which systemic immune events developing at a distance from the tumor reflect local response or resistance to immunotherapy. The importance of this cancer ‘macroenvironment’, which can be deciphered by comprehensive analysis of peripheral blood immune cell subsets, has been demonstrated in several cutting-edge preclinical reports, and is corroborated by intriguing data emerging from ICI-treated patients. In this review, we will provide the biological rationale underlying the potential of blood immune cell-based biomarkers in guiding treatment decision in immunotherapy-eligible NSCLC patients. Finally, we will describe new techniques that will facilitate the discovery of more immune cell subpopulations with potential to become predictive biomarkers, and reflect on ways and the remaining challenges to bring this type of analysis to the routine clinical care in the near future.
format Online
Article
Text
id pubmed-10401220
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-104012202023-08-05 Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer Marcos Rubio, Alvaro Everaert, Celine Van Damme, Eufra De Preter, Katleen Vermaelen, Karim J Immunother Cancer Review The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of non-small cell lung cancer (NSCLC), with these drugs now being evaluated at every stage of the disease. In contrast to these advances, little progress has been made with respect to reliable predictive biomarkers that can inform clinicians on therapeutic efficacy. All current biomarkers for outcome prediction, including PD-L1, tumor mutational burden or complex immune gene expression signatures, require access to tumor tissue. Besides the invasive nature of the sampling procedure, other disadvantages of tumor tissue biopsies are the inability to capture the complete spatial heterogeneity of the tumor and the difficulty to perform longitudinal follow-up on treatment. A concept emerges in which systemic immune events developing at a distance from the tumor reflect local response or resistance to immunotherapy. The importance of this cancer ‘macroenvironment’, which can be deciphered by comprehensive analysis of peripheral blood immune cell subsets, has been demonstrated in several cutting-edge preclinical reports, and is corroborated by intriguing data emerging from ICI-treated patients. In this review, we will provide the biological rationale underlying the potential of blood immune cell-based biomarkers in guiding treatment decision in immunotherapy-eligible NSCLC patients. Finally, we will describe new techniques that will facilitate the discovery of more immune cell subpopulations with potential to become predictive biomarkers, and reflect on ways and the remaining challenges to bring this type of analysis to the routine clinical care in the near future. BMJ Publishing Group 2023-08-03 /pmc/articles/PMC10401220/ /pubmed/37536935 http://dx.doi.org/10.1136/jitc-2023-007023 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Marcos Rubio, Alvaro
Everaert, Celine
Van Damme, Eufra
De Preter, Katleen
Vermaelen, Karim
Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
title Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
title_full Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
title_fullStr Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
title_full_unstemmed Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
title_short Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
title_sort circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401220/
https://www.ncbi.nlm.nih.gov/pubmed/37536935
http://dx.doi.org/10.1136/jitc-2023-007023
work_keys_str_mv AT marcosrubioalvaro circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer
AT everaertceline circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer
AT vandammeeufra circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer
AT depreterkatleen circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer
AT vermaelenkarim circulatingimmunecelldynamicsasoutcomepredictorsforimmunotherapyinnonsmallcelllungcancer